DigiMed Showcase: A new, high-impact track at Biotech Showcase
Taking place at Biotech Showcase, DigiMed Showcase will take place January 11–13, 2027 in San Francisco, CA.

About DigiMed Showcase
DigiMed Showcase is a high-visibility platform within Biotech Showcase, built to spotlight the full spectrum of technology-driven healthcare innovation—with a strong emphasis on MedTech, medical devices, digitally enabled care, and AI-powered drug discovery.
More than a presenting opportunity, DigiMed is a strategic stage to introduce and position your company’s vision, technology, and value proposition in front of an audience of decision-makers. From advanced devices and diagnostics to AI-driven drug discovery platforms and digital therapeutics, DigiMed brings together the companies redefining how we diagnose, treat, and manage disease—while enabling meaningful dialogue with the investors and partners shaping what comes next.
As the lines between MedTech, biopharma, and digital health continue to blur, this track creates a centralized destination for investors, pharma leaders, and strategic partners to discover scalable, investable innovation.
Core areas include MedTech and medical devices, digital health and therapeutics, AI and machine learning, drug discovery platforms, robotics, quantum computing, VR/AR, NLP and LLMs, brain-machine interfaces, bioprocessing, electroceuticals, and DNA/RNA synthesis.
What to expect
One-to-one meetings
Connect with leading scientists, innovators, investors, and industry professionals who are at the forefront of the TechBio revolution. Our partnering platform, partneringONE®, allows you to identify prospective partners using advanced search capabilities and manage all your meeting requests in one place.
Presenting companies
Experience a wealth of innovative presentations unveiling the latest technological innovations driving the next wave of biological breakthroughs.
Insightful program topics
Gain deep insights from expert speakers and panelists who will share their knowledge, experiences, and visions for the future of TechBio.
